31 Mar 2021 Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B Scribe Therapeutics has completed an oversubscribed $100-million Series B financing, with aims to further develop its suite of custom gene-editing and delivery technologies based on molecular engineering, as well ...
